Lataa...
Euglycemic DKA (euDKA) as a presentation of COVID‐19
COVID‐19 in the setting of SGLT2 inhibitor use may precipitate euglycemic DKA separate from known acute viral illness and dehydration precipitants. There should be consideration of proactive discontinuation of these medications in these patients.
Tallennettuna:
| Julkaisussa: | Clin Case Rep |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7753533/ https://ncbi.nlm.nih.gov/pubmed/33362928 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.3540 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|